June 23, 2022
Presentations & Publications
June 14, 2022
GEN Biotechnology: T Cell Therapies for Cancer
DownloadMay 4, 2022
Protein and Antibody Engineering Summit (PEGS 2022): Engineering an Injectable CD8-Targeted IL-12 with Strong Anti-Tumor Immunity and Improved Therapeutic Window
DownloadMay 4, 2022
Protein and Antibody Engineering Summit (PEGS 2022): Discovery and Characterization of Silent CD8 antibodies for Therapeutic Applications
DownloadApril 29, 2022
High-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4 T cell targets and mechanisms of immune escape
DownloadApril 27, 2022
Cell surface–tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy
DownloadNovember 18, 2021
Allelic variation in Class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2
DownloadJuly 22, 2021
Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
DownloadNovember 9, 2020
PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients
DownloadNovember 9, 2020
Adoptive transfer of T cells surface-tethered with IL-12 promotes antigen spreading for enhanced anti-tumor efficacy
DownloadSeptember 28, 2020
An Effective COVID-19 Vaccine Needs to Engage T Cells
DownloadNovember 9, 2019
Deep TLR PrimedTM T cells induce potent anti-tumor activity without systemic toxicity
DownloadNovember 8, 2019
Adoptive Transfer of Deep IL-12 Primed™ T-cells Increases Sensitivity to PD-L1 Blockade for Superior Efficacy in Checkpoint Refractory Tumors
DownloadNovember 8, 2019
Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity
DownloadNovember 8, 2019
Optimized process for manufacturing Deep-Primed™ T cells creates product with improved functional characteristics and reactivity against multiple tumor-associated antigens
DownloadApril 1, 2019
DeepTM IL-15 primed T cells synergize with PD-L1 blockade to overcome resistance to checkpoint immunotherapy
DownloadMarch 31, 2019
Surface-tethered IL-12 improves tumor-specific T cell therapy and enhances inflammatory activity in tumors without inducing systemic toxicities
DownloadMarch 11, 2019
Deciphering CD4+ T cell specificity using novel MHC–TCR chimeric receptors
DownloadNovember 10, 2018
DeepTM IL-15 Primed multi-targeted T cells demonstrate potent antigen-specific cytotoxic activity against human cancer cells
DownloadNovember 10, 2018
A fully-closed, high efficiency manufacturing technology platform for the production of T cell therapies targeting multiple tumor antigens
DownloadNovember 9, 2018
Tethering IL-12 to the surface of T cells induces broad immune activation and potent anti-tumor activity in mice without inducing systemic toxicities
DownloadNovember 9, 2018
Preclinical evaluation of Deep™ IL-15 Primed PMEL cells demonstrates highly improved safety compared to systemic administration of IL-15
DownloadOctober 1, 2018
T cell priming with Deep™ IL-15 improves preclinical safety compared to systemic IL-15, and increases in vivo persistence and activity
DownloadJuly 9, 2018
Enhancing T cell therapy through TCR-signalingresponsive nanoparticle drug delivery
DownloadApril 17, 2018
DeepTM IL-15 provides autocrine stimulation and expansion of autologous T cells driven by controlled concentrated release of IL-15
DownloadApril 17, 2018
T cell receptor signaling-responsive single chain IL-12 and IL-15 superagonist nanogel “backpacks” to enhance adoptive cell therapy in solid tumors
DownloadApril 17, 2018